In the latest trading session, 1.04 million Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) shares changed hands as the company’s beta touched 1.11. With the company’s most recent per share price at $2.06 changed hands at -$0.06 or -2.83% at last look, the market valuation stands at $170.00M. HEPA’s current price is a discount, trading about -134.47% off its 52-week high of $4.83. The share price had its 52-week low at $1.45, which suggests the last value was 29.61% up since then. When we look at Hepion Pharmaceuticals Inc.’s average trading volume, we note the 10-day average is 2.78 million shares, with the 3-month average coming to 2.30 million.
Analysts gave the Hepion Pharmaceuticals Inc. (HEPA) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended HEPA as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Hepion Pharmaceuticals Inc.’s EPS for the current quarter is expected to be -$0.19.
Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) trade information
Instantly HEPA was in red as seen in intraday trades today. With action -0.93%, the performance over the past five days has been red. The drop to weekly highs of 2.29 on Friday, 06/18/21 subtracted -2.83% to the stock’s daily price. The company’s shares are showing year-to-date downside of -3.20%, with the 5-day performance at -0.93% in the red. However, in the 30-day time frame, Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) is 24.71% up. Looking at the short shares, we see there were 1.32 million shares sold at short interest cover period of 0.84 days.
The consensus price target for the stock as assigned by Wall Street analysts is $5.50, meaning bulls need an upside of 62.55% from its recent market value. According to analyst projections, HEPA’s forecast low is $5.00 with $6.00 as the target high. To hit the forecast high, the stock’s price needs a -191.26% plunge from its current level, while the stock would need to soar -142.72% for it to hit the projected low.
Hepion Pharmaceuticals Inc. (HEPA) estimates and forecasts
As can be gleaned from the statistics, the company’s share value shot 12.17% over the past 6 months. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for Hepion Pharmaceuticals Inc. will rise 67.20%, while the growth in revenue is estimated to hit 72.50% for the next quarter.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 64.10%. The 2021 estimates are for Hepion Pharmaceuticals Inc. earnings to increase by 65.60%.
Hepion Pharmaceuticals Inc. (NASDAQ:HEPA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.14% of Hepion Pharmaceuticals Inc. shares while 23.72% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 23.75%. There are 23.72% institutions holding the Hepion Pharmaceuticals Inc. stock share, with Vanguard Group, Inc. (The) the top institutional holder. As of Mar 30, 2021, the company held 4.37% of the shares, roughly 3.33 million HEPA shares worth $6.13 million.
Blackrock Inc. holds the second largest percentage of outstanding shares, with 2.25% or 1.72 million shares worth $3.16 million as of Mar 30, 2021.
Among Mutual Funds, the top two as of Mar 30, 2021 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 2.07 million shares estimated at $3.81 million under it, the former controlled 2.71% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 1.44% of the shares, roughly 1.1 million shares worth around $2.02 million.